Single Molecule Counting (SMCxPRO & Erenna) Assay Services: Sensitive Cytokine Testing

MilliporeSigma Single Molecule Counting (SMCxPRO® & Erenna®)

Cytokine analysis utilizing Single Molecule Counting technology enables sub-pg/ml sensitivity for accurate measurement of low abundance biomarkers in normal or disease sera/plasma
Minimal sample dilution requirement with 4-Log+ dynamic range
High precision cytokine immunoassays provide reproducible data
Extensive analyte menu of over 40 different cytokine assays covering several disease areas including IFN-γ, IL-1a, IL-1b, IL-4, IL-6, IL-8, IL-10, IL-13, IL-15, IL-17A, IL-17F, IL-17 heterodimer, IL-23, GLP-1, and TNF-α
See below for representative data

Employing MilliporeSigma's Single Molecule Counting (SMC) technology with robust microparticle-based SMCxPRO® & Erenna® immunoassays, PBL’s cytokine detection services can provide scientists with sub-pg/ml level measurements of low-abundance analytes in healthy or disease sera and plasma.

To enable scientific community to overcome challenges through high-quality services

Request an Assay Services Quote

Key Features offered by Single Molecule Counting Technology on SMCxPRO and Erenna Platforms:

Enables sub-pg/ml sensitivity for accurate measurement of low abundance biomarkers in serum, plasma or other complex matrices
Requires minimal sample dilution with a 4-Log+ dynamic range
Provides high precision and reproducible data
Extensive analyte menu of over 30 different cytokine assays covering several disease areas

PBL Singulex Erenna shows the ability to measure low levels of IL-1 Beta in Plasma samples (Heparin, Citrate, and EDTA) — **Figure 1.** Median levels of IL-1b (Interleukin 1 Beta) in Plasma Samples (Heparin, Citrate and EDTA)

2 Citations:

Passeron, T. et al., (2023), "A Phase IIIb, Multicentre, Interventional, Randomised, Placebo-Controlled Clinical Trial Investigating the Efficacy and Safety of Guselkumab for the Treatment of Nonpustular Palmoplanter Psoriasis (G-PLUS)", Dermatologic Therapy, DOI: 10.1155/2023/9967747 (link)

Morita, A. et al., (2022), "Effect of guselkumab on serum biomarkers in Japanese palmoplanter pustulosis patients in randomized phase 3 study", JEADV Clinical Practice, DOI: 10.1002/jvc2.73 (link)